Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | NRP1 | O14786 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18057235 | 0.93 | PYGL (0.33) | KCNH2PYGLMAPTPER2CRY1 | |
| SCHEMBL18057233 | 0.92 | PYGL (0.35) | PYGLMAPTLMNAPER2CRY1 | |
| SCHEMBL18057246 | 0.88 | MMP2 (0.38) | PYGLPER2CRY1CRY2 | |
| SCHEMBL18057237 | 0.87 | PER2 (0.35) | PYGLPER2CRY1CRY2 | |
| SCHEMBL16669968 | 0.85 | KCNH2 (0.33) | KCNH2NRP1PYGLMAPTGAA | |
| SCHEMBL16669969 | 0.85 | KCNH2 (0.33) | KCNH2NRP1PYGLMAPTGAA | |
| SCHEMBL19999761 | 0.84 | PYGL (0.34) | PYGLPER2CRY1CRY2 | |
| SCHEMBL19999758 | 0.82 | PYGL (0.36) | PYGLMAPTLMNAPER2CRY1 | |
| SCHEMBL19999763 | 0.82 | PYGL (0.37) | PYGLPER2CRY1CRY2 | |
| SCHEMBL19999769 | 0.81 | OPRD1 (0.34) | PYGLPER2CRY1CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR1E, POLR1G | KCNH2 4596/4885NRP1 4176/4885PYGL 641/4885 |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR1G, POLR1E | KCNH2 4630/4885NRP1 4199/4885PYGL 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.